Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutic (NQ: HALO )

52.06 +0.51 (+0.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,278,818
Open 52.40
Bid (Size) 52.06 (19)
Ask (Size) 53.00 (5)
Prev. Close 51.55
Today's Range 51.72 - 52.92
52wk Range 32.83 - 53.00
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded to 95 Monday, up from 68 a day earlier. 
Via Investor's Business Daily
Decoding 12 Analyst Evaluations For Halozyme Therapeutics
Via Benzinga

Performance

YTD
+39.24%
+39.24%
1 Month
+20.84%
+20.84%
3 Month
+28.80%
+28.80%
6 Month
+39.31%
+39.31%
1 Year
+49.43%
+49.43%

More News

Read More
NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
Via Chartmill
Arcellx Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
Via Investor's Business Daily
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
NASDAQ:HALO, a growth stock which is not overvalued.
Via Chartmill
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
Via Chartmill
The 3 Best Healthcare Stocks to Buy in June 2024
Via InvestorPlace
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
Via Investor's Business Daily
Krystal Biotech Stock Sees RS Rating Jump To 91
Via Investor's Business Daily
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Via Benzinga
Halozyme Therapeutics Scores RS Rating Jump To 91
Via Investor's Business Daily
This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Halozyme Therapeutics +13% On Thursday: What's Going On?
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday
Via Benzinga
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts
Via Benzinga
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
Via Chartmill
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
Via Investor's Business Daily
The 3 Best Biotech Stocks to Buy in May 2024
Via InvestorPlace
When you look at NASDAQ:HALO, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.